Targeting the endothelin pathway in the idiopathic pulmonary fibrosis: the role of bosentan

Background: Idiopathic pulmonary fibrosis (IPF) is a rapidly lethal disease characterized by anarchic, progressive fibrosis. Pulmonary fibrosis is the result of interactions between many effector cells and cytokines and better understanding of this can help with identification of novel therapeutic targets. Objective: To evaluate the role of the endothelin-1 (ET-1) pathway in IPF pathogenesis and the effects of therapeutic targeting with bosentan, an ET-1 antagonist. Methods: Data on ET-1's pathogenic involvement in IPF and the preclinical and clinical data on bosentan in this context are discussed and analyzed. A parallel overview of existing and upcoming therapies for IPF is presented. Conclusions: Bosentan is a promising antifibrotic therapy for IPF and clinical data on its long-term efficacy support its use.

[1]  M. Arzt,et al.  Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan , 2010, Respiratory Physiology & Neurobiology.

[2]  M. Raza.  BUILD-1: A Randomized Placebo-Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis , 2009 .

[3]  J. Wilson,et al.  Challenges in pulmonary fibrosis: 7 · Novel therapies and lung transplantation , 2008, Thorax.

[4]  R. D. du Bois,et al.  Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. , 2007, Arthritis and rheumatism.

[5]  E. Gabbay,et al.  Review of bosentan in the management of pulmonary arterial hypertension , 2007, Vascular health and risk management.

[6]  P. Shaul,et al.  Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1. , 2007, American journal of respiratory cell and molecular biology.

[7]  H. Chapman,et al.  Endothelin-1 as initiator of epithelial-mesenchymal transition: potential new role for endothelin-1 during pulmonary fibrosis. , 2007, American journal of respiratory cell and molecular biology.

[8]  W. Seeger,et al.  Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study , 2007, European Respiratory Journal.

[9]  P. Shaul,et al.  Endothelin-1 Induces Alveolar Epithelial–Mesenchymal Transition through Endothelin Type A Receptor–Mediated Production of TGF- (cid:2) 1 , 2007 .

[10]  H. Collard,et al.  Acute exacerbations of idiopathic pulmonary fibrosis. , 2007, American journal of respiratory and critical care medicine.

[11]  F. Martinez,et al.  Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. , 2006, American journal of respiratory and critical care medicine.

[12]  J. Varga,et al.  Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers , 2006, Expert opinion on pharmacotherapy.

[13]  S. Antoniu.  Pirfenidone for the treatment of idiopathic pulmonary fibrosis , 2006, Expert opinion on investigational drugs.

[14]  M. Kolb,et al.  Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls. , 2006, Proceedings of the American Thoracic Society.

[15]  B. Willis,et al.  Epithelial origin of myofibroblasts during fibrosis in the lung. , 2006, Proceedings of the American Thoracic Society.

[16]  L. Armstrong,et al.  The effect of Bosentan on VEGF isoform and receptor expression by human pulmonary microvascular endothelial cells (HMVEC-1, Cambrex) and human lung fibroblasts (FB) , 2006 .

[17]  J. Horowitz,et al.  Idiopathic Pulmonary Fibrosis , 2006, Treatments in respiratory medicine.

[18]  Johny Verschakelen,et al.  High-dose acetylcysteine in idiopathic pulmonary fibrosis. , 2005, The New England journal of medicine.

[19]  Demosthenes Bouros,et al.  Current and future therapeutic approaches in idiopathic pulmonary fibrosis , 2005, European Respiratory Journal.

[20]  A. Malhotra,et al.  Interferon-γ1b Therapy in Idiopathic Pulmonary Fibrosis: A Metaanalysis , 2005 .

[21]  R. Barst,et al.  Endothelin receptor antagonists for pulmonary arterial hypertension. , 2005, The Cochrane database of systematic reviews.

[22]  F. Martinez,et al.  Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy , 2004, Expert opinion on pharmacotherapy.

[23]  P. Hasleton,et al.  Angiogenic cytokines in patients with idiopathic interstitial pneumonia , 2004, Thorax.

[24]  Yunliang Chen,et al.  Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. , 2004, Molecular biology of the cell.

[25]  F. Martinez,et al.  Mechanisms of pulmonary fibrosis. , 2004, Annual review of medicine.

[26]  G. Raghu,et al.  A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. , 2004, The New England journal of medicine.

[27]  M. Kasper,et al.  Localization of endothelin receptors in bleomycin-induced pulmonary fibrosis in the rat , 2000, Histochemistry and Cell Biology.

[28]  G. Izbicki,et al.  Role of interferon-γ in the evolution of murine bleomycin lung fibrosis , 2003 .

[29]  R. D. du Bois,et al.  Increased Vitronectin and Endothelin-1 in the Breath Condensate of Patients with Fibrosing Lung Disease , 2003, Respiration.

[30]  R. Strawderman,et al.  Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. , 2001, The American journal of medicine.

[31]  A. Pardo,et al.  Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy , 2001, Annals of Internal Medicine.

[32]  T. Seemungal,et al.  Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease , 2001, Thorax.

[33]  G. Trakada,et al.  Arterial and bronchoalveolar lavage fluid endothelin-1 concentration in asthma. , 2000, Respiratory medicine.

[34]  H. Neumayer,et al.  Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. , 2000, American journal of respiratory cell and molecular biology.

[35]  F. Martinez,et al.  Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. , 2000, Chest.

[36]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[37]  K. J. Macleod,et al.  Sputum endothelin-1 is increased in cystic fibrosis and chronic obstructive pulmonary disease. , 1999, The European respiratory journal.

[38]  J. Samet,et al.  Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts , 1998, Thorax.

[39]  R. Chambers,et al.  Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. , 1998, American journal of respiratory cell and molecular biology.

[40]  N. Goldsack,et al.  Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. , 1998, Pulmonary pharmacology & therapeutics.

[41]  R. Novick,et al.  Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease , 1998, The Lancet.

[42]  R. D. du Bois,et al.  Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. , 1997, The American journal of pathology.

[43]  R. Michel,et al.  Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. , 1997, American journal of respiratory and critical care medicine.

[44]  B. Corrin,et al.  Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. , 1997, American journal of respiratory cell and molecular biology.

[45]  S. Oparil,et al.  Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. , 1995, Journal of applied physiology.

[46]  L. Fasano,et al.  Endothelin-1 in idiopathic pulmonary fibrosis. , 1995, Journal of clinical pathology.

[47]  M. Sheppard,et al.  Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis , 1993, The Lancet.

[48]  E. Verrier.  The vascular endothelium: friend or foe? , 1993, The Annals of thoracic surgery.

[49]  A. Shah.  Vascular endothelium. , 1992, British journal of hospital medicine.

[50]  G. Raghu,et al.  Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. , 1991, The American review of respiratory disease.

[51]  R. McAnulty,et al.  Oral N-acetylcysteine reduces bleomycin-induced collagen deposition in the lungs of mice. , 1991, The European respiratory journal.